Traders Sell Shares of Amgen Inc. (AMGN) on Strength (AMGN)
Investors sold shares of Amgen Inc. (NASDAQ:AMGN) on strength during trading hours on Thursday. $114.88 million flowed into the stock on the tick-up and $218.28 million flowed out of the stock on the tick-down, for a money net flow of $103.40 million out of the stock. Of all equities tracked, Amgen had the 0th highest net out-flow for the day. Amgen traded up $4.12 for the day and closed at $177.77
AMGN has been the subject of several research reports. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $189.00 price target on shares of Amgen in a research report on Friday, June 30th. BidaskClub raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. Jefferies Group LLC reissued a “hold” rating and issued a $180.00 price target on shares of Amgen in a research report on Monday, May 22nd. Credit Suisse Group set a $177.00 price target on shares of Amgen and gave the company a “hold” rating in a research report on Friday, July 14th. Finally, Morgan Stanley lifted their price target on shares of Amgen from $183.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, June 13th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $186.04.
The stock has a market capitalization of $130.40 billion, a price-to-earnings ratio of 16.28 and a beta of 1.35. The stock has a 50 day moving average of $173.78 and a 200 day moving average of $168.57.
Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.84 EPS. On average, equities research analysts expect that Amgen Inc. will post $12.57 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be issued a $1.15 dividend. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.57%. The ex-dividend date is Tuesday, August 15th. Amgen’s dividend payout ratio (DPR) is 41.93%.
Large investors have recently modified their holdings of the stock. Oakmont Partners LLC purchased a new stake in shares of Amgen during the first quarter worth $989,000. Honkamp Krueger Financial Services Inc. raised its position in Amgen by 4.7% in the first quarter. Honkamp Krueger Financial Services Inc. now owns 5,327 shares of the medical research company’s stock valued at $874,000 after buying an additional 239 shares during the last quarter. Private Trust Co. NA raised its position in Amgen by 16.4% in the first quarter. Private Trust Co. NA now owns 7,092 shares of the medical research company’s stock valued at $1,163,000 after buying an additional 999 shares during the last quarter. Prospera Financial Services Inc raised its position in Amgen by 36.6% in the first quarter. Prospera Financial Services Inc now owns 2,829 shares of the medical research company’s stock valued at $462,000 after buying an additional 758 shares during the last quarter. Finally, First Command Financial Services Inc. raised its position in Amgen by 1.1% in the first quarter. First Command Financial Services Inc. now owns 1,547 shares of the medical research company’s stock valued at $254,000 after buying an additional 17 shares during the last quarter. 78.12% of the stock is owned by institutional investors and hedge funds.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).